Reference
Liu Y, et al. Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine. Leukemia and Lymphoma 55: 447-449, No. 2, Feb 2014. Available from: URL: http://doi.org/10.3109/10428194.2013.802315 - USA
Rights and permissions
About this article
Cite this article
Azacitidine. Reactions Weekly 1525, 21 (2014). https://doi.org/10.1007/s40278-014-4536-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-014-4536-9